ProfileGDS5678 / 1432129_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 49% 49% 48% 49% 49% 46% 49% 49% 50% 51% 50% 49% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1722548
GSM967853U87-EV human glioblastoma xenograft - Control 23.1705349
GSM967854U87-EV human glioblastoma xenograft - Control 33.1663249
GSM967855U87-EV human glioblastoma xenograft - Control 43.0678148
GSM967856U87-EV human glioblastoma xenograft - Control 53.1212749
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.27949
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1623446
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1506349
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1552549
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1649350
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2132651
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1509750
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1708749
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1109947